Market News & Trends
Spark Therapeutics Announces New Positive Data From Continuation of Phase III Trial
Spark Therapeutics recently announced new data from the continuation of the Phase III trial of voretigene neparvovec (formerly referred to as SPK-RPE65), its most advanced…
Scientists Find Important Clue to Restoring Muscle Function
ChromaDex Corp. recently announced that University of Pennsylvania researchers have uncovered an important clue as to why our muscles weaken as we age, and how…
Pluristem’s Phase III Study Wins $8-Million Grant
Pluristem Therapeutics Inc. recently announced that its critical limb ischemia (CLI) program in the European Union has been awarded an $8-million grant. The grant is…
Amphivena Therapeutics Announces Acceptance of IND Application
Amphivena Therapeutics, Inc. recently announced that the US FDA has accepted an investigational new drug (IND) application for AMV564, the company’s proprietary T-cell redirecting bispecific…
Allergan Sales to Consolidate Four New Jersey Locations
The state Economic Development Authority approved Allergan's application for Grow NJ tax breaks that it said would keep 1,019 workers in the state, and add…
NIH Using PharmaJet in DNA Vaccine Clinical Trial
PharmaJet recently announced that the National Institutes of Health will use the PharmaJet Stratis needle-free device in a DNA vaccine clinical trial for the Zika…
OmniComm Systems Signs Multi-Million Dollar, 5-Year Agreement
OmniComm Systems, Inc. recently announced that one of the top five medical research universities in the US, selected OmniComm TrialMaster EDC and related services to…
Catalyst Biosciences Announces Agreement to Sell Three NNR Assets to Attenua
Catalyst Biosciences, Inc. recently announced it has entered into a definitive agreement to sell to Attenua, Inc. certain oral Neuronal Nicotinic Receptor (NNR) assets that…
Mayne Pharma Acquires Portfolio From Teva & Allergan
Mayne Pharma has recently completed its $652-million transaction with Teva and Allergan, taking ownership of 37 approved and five filed generic pharmaceutical products. This transaction…
Catalent Biologics & Zumutor Collaborate to Develop Antibodies With Enhanced ADCC Activity
Catalent Pharma Solutions and Zumutor Biologics Inc. recently announced a successful research study, combining Catalent’s proprietary GPEx technology and Zumutor’s fucose knockout platform, to create…
Abeona Therapeutics Uses Next-Generation AAV-Based Gene Therapy
Adeno-Associated Virus (AAV) vectors are currently among the most frequently used viral vectors for gene therapy. At recent meetings of the American Society for Gene…
Top Three Therapy Areas Account for 68% of Overall Pharmaceutical Industry Pipeline
The top three therapy areas – namely oncology, infectious diseases, and central nervous system (CNS) disorders – accounted for a combined 68% of the overall…
Top Three Therapy Areas Account for 68% of Overall Pharmaceutical Industry Pipeline
The top three therapy areas – namely oncology, infectious diseases, and central nervous system (CNS) disorders – accounted for a combined 68% of the overall…
Mayne Pharma Receives FDA Approval; Acquires Portfolio From Teva & Allergan
Mayne Pharma Inc. has received approval from the US FDA to market dofetilide capsules, a generic alternative to Tikosyn, an anti-arrhythmic agent used to treat…
MilliporeSigma Expands Excipients Portfolio, Adding Polymers for Sustained Release Injectables
Allows for more precise control of release kinetics Enables development of drugs requiring fewer injections for enhanced patient comfort and compliance Billerica, Massachusetts, July 12,…
Mayne Pharma Receives FDA Approval; Acquires Portfolio From Teva & Allergan
Mayne Pharma Inc. has received approval from the US FDA to market dofetilide capsules, a generic alternative to Tikosyn, an anti-arrhythmic agent used to treat…
MilliporeSigma Expands Excipients Portfolio, Adding Polymers for Sustained Release Injectables
Allows for more precise control of release kinetics Enables development of drugs requiring fewer injections for enhanced patient comfort and compliance Billerica, Massachusetts, July 12,…
Tesaro Raises $377 Million
TESARO, Inc. recently announced it has commenced an underwritten public offering of $300 million of its common stock. In connection with this offering, TESARO plans…
Merck Provides Results of Pivotal Study That Confirms Addition of Erbitux to FOLFOX Significantly Improves Outcomes
Merck presented data at the ESMO 18th World Congress on Gastrointestinal Cancer (WCGC) from the pivotal Phase III TAILOR study in patients from China, the…
Aeterna Zentaris & Orient Europharma Sign License Agreement
Aeterna Zentaris Inc. and Orient EuroPharma Co., Ltd. recently announced the signing of an exclusive license agreement between the company and Cyntec Co., Ltd., an…
